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ARTICLE IN PRESSLetter to the Editors-in-ChiefAutomated APTT cycle for the rapid identification of plasma
prekallikrein deficiency
Very prolonged activated partial thromboplastin time (APTT) is a
challenging issue for coagulation laboratories and warrants further
investigation, once preanalytical or analytical causes have been
excluded. Abnormal APTT may be due to anticoagulation therapy,
primarily heparin, which can be present in the specimen as a
therapeutic or contaminant agent, or it may be due to a coagulation
factor deficiency, either congenital or acquired (e.g., presence of
specific inhibitors directed against single coagulation factors or non-
specific inhibitors, such as Lupus Anticoagulants). When haemophilia
(A, B or C) and lupus anticoagulants (LAs) have been ruled out,
abnormalities in the so-called contact system, which includes plasma
prekallikrein, factor XII (FXII) and high molecular weight kininogen
(HK), should be investigated. Prekallikrein, also known as Fletcher
Factor, is converted to its active form (kallikrein) by FXII that can
autoactivate on negatively charged artificial surfaces or in the
presence of various biological substances [1–4]. Plasma kallikrein in
turn further activates FXII with consequent amplification of the
process. Prekallikrein may also be activated by the serine protease
prolylcarboxypeptidase [5] and by heat shock protein 90 [6] in a FXII-
independent way. Deficiency of prekallikrein, which is not generally
associated with bleeding tendency and is inherited as an autosomal
recessive trait [7,8], is characterised by severely prolonged APTT that
progressively shorten and even normalise when the preincubation
time of plasma with the reagent containing a contact activator is
extended to at least 10-20 minutes [9]. This behaviour is due to a
bypass mechanism that allows that sufficient activated FXII is
generated to further activate the coagulation factor XI [10]. Shortening
of prolonged APTT with extended incubation time of plasma with a
contact activator before recalcification was described in LA samples
but, in this case, did not achieve normalisation [11,12]. APTT assays
with extended incubation times are not commonly available on
automated coagulometers; furthermore, the manual tilt-tube method
is not feasible in all laboratories.
We have implemented, in the ACL Elite coagulometer (Instru-
mentation Laboratory – IL, Milan, Italy), an APTT cycle (Prekallikrein-
APTT) that simultaneously performs two APTTs for each sample, with
standard (5 min) and extended (20 min) preincubation times. This
modified APTT test allows for the rapid and specific identification of
prekallikrein deficiency.
Plasma sampling
Blood samples, collected in vacuum tubes containing 1/10 vol of
0.109 Msodiumcitrate (2.7 mLBectonDickinsonVacutainerRutherford,
New Jersey, USA) using 21 G needles, were centrifuged at 2000 g for
30 min at room temperature. Plasma was stored at -80 °C until testing.
Samples were obtained from normal subjects (40), patients with
prekallikrein deficiency (5), patients with FII, FV, FVIII, FIX, FXI and
FXII deficiency (29) (factor activity b50%, with or without inhibitors),0049-3848/$ – see front matter © 2010 Elsevier Ltd. All rights reserved.
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with lupus anticoagulants (36), on oral anticoagulant (51) and
patients undergoing heparin therapy (10).
In addition, commercial lyophilised plasmas from patients con-
genitally deficient in prekallikrein (George King Bio-Medical, Inc.,
Overland Park, KS, USA), in HK (Technoclone GmbH, Wien, Austria)
and in FII, FV, FX, FVIII, FIX, FXI and FXII (IL) were tested.
The APTT reagent used for the study was APTT-SP (IL), which
contains synthetic phospholipids andmicronised silica as an activator.
Plasma prekallikrein activity was determined with the ACL Elite
using prekallikrein-deficient plasma as a substrate (Technoclone
GmbH, Wien, Austria), APTT-SP as a reagent and an internal reference
pool, defined to contain 100% prekallikrein activity.Prekallikrein-APTT cycle
The Prekallikrein-APTT cycle, implemented in the ACL Elite, has
the same characteristics (reagents, volumes, acquisition parameters
and raw data elaboration algorithm) as the basic “APTT SPe” test
provided by the manufacturer; however, in the Prekallikrein-APTT
cycle, each sample is processed twice during the same analysis:
plasma is loaded into the rotor and incubated for twentyminutes with
the cephalin-activator reagent; meanwhile, the same plasma sample
is loaded again with the reagent and incubated for five minutes
(Table 1). Calcium chloride is then added. At the end of the
Prekallikrein-APTT cycle, two APTT results are obtained: one for the
20-min incubation time and one for the 5-min incubation time.Statistical analysis
The Wilcoxon test for paired data was used for within-group
comparisons of 5-min APTT vs. 20-min APTT. The Kruskal-Wallis and
theMann-Whitney U tests were used for between-group comparisons
of the 20-min APTT results. Significances of all multiple comparisons
were adjusted by Bonferroni. Stata/SE 11.0 (The StataCorp, College
Station, Texas, USA) was used for all statistical analyses.Results
The observed ranges (min-max) for the 5-min and 20-min
Prekallikrein-APTT obtained for all samples are reported in Table 2.
The prekallikrein-deficient samples showed a rather wide range of
5-min APTT results with prekallikrein activity from 0.66 to 1.31%.
The 20-min APTT results were not significantly different from the
5-min APTT results in the contact phase factor deficiencies (FXII, HK)
and in the normal subjects (Table 2, within-group comparisons). In all
other cases, the 20-min APTT results were significantly different from
the 5-min APTT ones; however, the 20-min incubation led to
shortened coagulation times only in the prekallikrein-deficient and
LA samples, whereas in all other cases an even further prolongation of
APTT was observed.rapid identification of plasma prekallikrein deficiency, Thromb Res
Table 1
Prekallikrein-APTT cycle: analysis parameters.
Loading step Timing constraint Ramp Centrifugation time
20-min incubation-sample Delay at completion 1 sec Enabled* 60 sec
Optical reference Step length 900 sec - -
5-min incubation-sample Set timer 300 sec Enabled* 60 sec
*inter-ramp interval: 3 seconds; sec, seconds.
Table 2
Prekallikrein-APTT: observed ranges (seconds) and statistical analyses.
Groups of samples studied n Prekallikrein-APTT
Observed ranges
Within-group#
comparisons
Between-group§
comparisons
5-min
sec
20-min
sec
p-values p-values
Prekallikrein deficiency* 6 82.2 – 159.0 26.7 – 36.0 0.0312 0.1509 ns
FXII, HK (contact phase) factor deficiencies* 7 40.5 – N247.0 38.5 – 196.0 0.813 ns b0.00005
Other factor deficiencies*
(FII, FV, FX, FVIII, FIX, FXI, AVWD)
33 39.2 – 151.0 37.7 – 172.0 0.0159 b0.00005
Oral Anticoagulant therapy 51 37.5 – 92.9 37.2 – 112.0 0.0317 b0.00005
Lupus anticoagulants 36 48.7 – 217.0 36.2 – 202.0 b0.0001 b0.00005
Heparin therapy 10 38.5 – 147.0 43.5 – N247.0 0.020 b0.00005
Normal subjects 40 23.7 – 34.5 23.5 – 33.0 0.3922 ns /
* commercial plasmas included.
# comparison of 5-min APTT with 20-min APTT (Wilcoxon test for paired data; significance at pb0.05).
§ comparison of 20-min APTT results of normal subjects with all the other groups (Mann-Whitney U test; significance at pb0.00238).
sec, seconds; ns, not significant.
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deficient samples were not statistically different from those obtained
for the normal subjects, whereas values provided by all other groups
of patientsmaintained a statistical difference (Table 2, between-group
comparisons). These data showed that, when incubation of plasma
with the activator reagent was extended to 20 minutes before
recalcification, the normalisation of the very prolonged APTT was
specific for prekallikrein deficiency and it was not observed in FXII and
HK deficiencies.
In summary, a simple and completely automated screening cycle
(lasting about 30 minutes), with the simultaneous determination of
APTT after 5-min and 20-min preincubations of plasma with an
activator, was implemented in the automated coagulometer ACL Elite.
Normalisation of prolonged APTT with the 20-min preincubation time
was observed only in prekallikrein-deficient samples and not in all the
other conditions investigated (contact phase or congenital/acquired
factor deficiency, LA presence, anticoagulation). This modified APTT
cycle implemented in the ACL Elite could represent a rapid, specific
and inexpensive screening test for prekallikrein deficiency in the
workup of severely prolonged APTT.
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